New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions
PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Read More
Oncology Consultants Joins Agendia’s FLEX Big Data Registry Study
PRESS RELEASE Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Read More
Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients
PRESS RELEASE Latest Results from the I-SPY 2 Trial at Read More
Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines
PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Read More
Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China
For the first time, early-stage breast cancer patients and their Read More
US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology
Dataset of up to 10,000 full genome profiles matched with Read More
An Update on Agendia’s Precision Oncology Achievements in Breast Cancer
As we close out the first half of 2018, I’d Read More
Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations
IRVINE, CA and AMSTERDAM, NETHERLANDS – 25 July 2018 – Read More
An Open Letter to Women With Early-Stage Breast Cancer and Their Healthcare Teams:
One of the biggest questions that early-stage breast cancer patients Read More
Key Studies at the American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrate MammaPrint and BluePrint’s Utility in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients
New data from the I-SPY 2 trial highlights residual cancer Read More
